Because increased CXCR3 levels are indicative of poor survival rates, and targeted silencing of Cxcr3 inhibits the proliferation of hepatocellular carcinoma cells31, these findings support the present results showing that celecoxib-specific inhibition of growth and/or proliferation might partially contribute to suppression of the CXCL10/CXCR3 axis in GSCs. This evidence concerns the gene CXCL10 and hepatocellular carcinoma.